First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma
XOMA Corporation (XOMA)
Last xoma corporation earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xoma.com/investor-relations
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today that gevokizumab, an anti-IL1ß monoclonal antibody that XOMA discovered and initially developed, is now actively progressing in a Novartis oncology development program. The antibody candidate is being evaluated to determine the appropriate dose, as well as preliminary safety and efficacy, in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer, and metastatic renal cell carcinoma. Recently the first patient was dosed with gevokizumab in the dose-finding portion of the study. “This is an important milestone both for XOMA and for gevokizumab. Gevokizumab was XOMA’s primary focus for almost a decade,” commented Jim Neal, Chief Executive Officer of XOMA. “We are pleased to see gevokizumab re-enter clinical development under the guidance of Novartis, and we are grateful to the patients and their f
Show less
Read more
Impact Snapshot
Event Time:
XOMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XOMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XOMA alerts
High impacting XOMA Corporation news events
Weekly update
A roundup of the hottest topics
XOMA
News
- XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) [Yahoo! Finance]Yahoo! Finance
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)GlobeNewswire
- XOMA Corporation Announces Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- XOMA Corporation Announces Closing of Tender OfferGlobeNewswire
XOMA
Earnings
- 11/7/23 - Miss
XOMA
Sec Filings
- 4/25/24 - Form 8-K
- 4/3/24 - Form 8-K
- 4/2/24 - Form ARS
- XOMA's page on the SEC website